Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma

Oncotarget
Tiansuo ZhaoJihui Hao

Abstract

Treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has greatly improved clinical outcomes in patients with diffuse large B-cell lymphoma (DLBCL) compared with CHOP. The mechanism of rituximab-induced cell death is poorly understood. We found that rituximab does not enhance the directly killing efficacy of CHOP, as tested on a panel of DLBCL cell lines. Rituximab induced a rapid release of HMGB1 (High mobility group protein B 1). This release is independent of cell death but significantly correlated with an inhibition on STAT3 activity. In the resting state, HMGB1 co-localizes and interacts with STAT3 in the nucleus of DLBCL cells. Treatment with rituximab breaks this binding and triggers HMGB1 release. Treatment with R-CHOP but not CHOP significantly increased plasma HMGB1 and decreased IL-10 concentrations in DLBCL patients compared with controls. The conditioned medium from rituximab-treated DLBCL cells is able to trigger dendritic cell maturation, phagocytosis, and IFN-γ secretion by cytotoxic T cells. In conclusion, our results demonstrate that rituximab induces an inhibition on STAT3 activity, leading to increased HMGB1 release and decreased IL-10 secretion, which elicits immu...Continue Reading

References

Jul 1, 1994·The Journal of Experimental Medicine·N RomaniG Schuler
Oct 23, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D G MaloneyR Levy
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Sep 15, 1999·Proceedings of the National Academy of Sciences of the United States of America·J M BrickmanM Ptashne
Apr 4, 2003·Current Opinion in Genetics & Development·Alessandra Agresti, Marco E Bianchi
Apr 23, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Qi LiElise F Stanley
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Dec 26, 2006·Nature Medicine·Michel ObeidGuido Kroemer
Sep 5, 2007·Molecular Immunology·Martin J GlennieRonald P Taylor
Nov 6, 2007·Immunological Reviews·Marco E Bianchi, Angelo A Manfredi
Sep 24, 2009·Haematologica·Sean H LimMark S Cragg
Mar 3, 2010·Annual Review of Immunology·Gary P SimsAnthony J Coyle
Mar 31, 2010·Seminars in Hematology·George J Weiner
Jan 12, 2011·Annual Review of Immunology·Ulf Andersson, Kevin J Tracey
Mar 23, 2012·Nature Reviews. Cancer·Andrew M ScottLloyd J Old
Nov 16, 2012·Nature Reviews. Cancer·Dmitri V KryskoPeter Vandenabeele
Nov 20, 2012·Annual Review of Immunology·Guido KroemerLaurence Zitvogel
Jun 26, 2013·Immunology and Cell Biology·Kerrilyn R DienerJohn D Hayball
Jul 16, 2013·Cell Death and Differentiation·I MartinsG Kroemer
Nov 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xin HuangKai Fu
Aug 13, 2014·Oncotarget·Oliver KeppGuido Kroemer
Jan 24, 2015·Nature Communications·Chen ZhuVijay K Kuchroo
Mar 20, 2015·Nature Reviews. Cancer·Pavan BachireddyCatherine J Wu

❮ Previous
Next ❯

Citations

Aug 4, 2018·Frontiers in Immunology·A Razzaque Ahmed, Srinivas Kaveri
Dec 7, 2017·Oncoimmunology·Abhishek D GargLorenzo Galluzzi
Jul 15, 2020·Journal of Hematology & Oncology·Shunling YuanJi Zhang
Jan 7, 2020·Médecine sciences : M/S·Claire Deligne, Laurent Gros

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
co-IP
ELISA
Fluorescence microscopy
density
FCS

Software Mentioned

WCIF ImageJ
ImageJ
GraphPad Prism

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.